Clinical Trials Logo
  1. Home
  2. Nash
  3. NCT06322628

A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of VSA006 in Chinese NASH Patients

Nash Clinical Trial

Official title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of VSA006 Injection in Chinese Adult Patients With Nonalcoholic Steatohepatitis (NASH)

Clinical Trial Summary

Human genetic studies have shown that loss of function (LOF) mutations in HSD17β13 gene have a protective effect on the progression of alcohol-related and non-alcohol-related liver diseases, such as NASH, without significant adverse phenotypes. VSA006 is a siRNA drug targeting HSD17β13 mRNA in the liver and reduce the protein level of HSD17β13. Based on phase 1 study results in healthy volunteers and NASH/suspected NASH patients, this phase 2 study is designed to evaluate the efficacy, safety, PK profiles and immunogenicity of VSA006 in Chinese NASH patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06322628
Study type Interventional
Source Visirna Therapeutics HK Limited
Contact
Status Not yet recruiting
Phase Phase 2
Start date April 2024
Completion date July 2026
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05479721 - LITMUS Imaging Study
Recruiting NCT06308757 - Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis N/A
Completed NCT02923154 - Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH) Phase 2
Withdrawn NCT03980912 - Validation of the LiverFASt Test and the Associated Fibrosis Staging Scores Compared to Liver Tissue Pathology Via Liver Biopsy
Terminated NCT04565717 - A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) Phase 1
Recruiting NCT04302051 - Assessment of Fatty Liver With Thermo-acoustic Device
Recruiting NCT05327127 - Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis Phase 2
Completed NCT06348706 - Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes Phase 3
Recruiting NCT05935488 - Early Liver Disease Breath Detection
Active, not recruiting NCT06315361 - DIAbetes and NAFLD
Completed NCT03187496 - Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers. Phase 1
Recruiting NCT04442334 - The European NAFLD Registry
Recruiting NCT06338969 - The Impact of Different Carbohydrate Restriction After a Gastric Bypass on the Ketosis and Ketoacidosis N/A
Completed NCT05193916 - A Phase II Clinical Trial of Chiglitazar for NASH Phase 2
Active, not recruiting NCT05669677 - Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease
Not yet recruiting NCT04783116 - Plant Stanols and Liver Inflammation in Overweight and Obese Children N/A
Recruiting NCT06193629 - A Multicenter, Double-blind, Placebo-randomized Controlled Clinical Study on the Treatment of Non-alcoholic Steatohepatitis With Tibetan Drug Langqing Atar N/A
Completed NCT04006145 - A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH Phase 2
Recruiting NCT04232293 - Screening of Liver Fibrosis Using Blood Tests in Patients With Type 2 Diabetes Mellitus N/A
Recruiting NCT06410924 - A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH Phase 2